Arkolith/Insider Trading/ZYNE/Form 4

Parker Albert P

Chief Legal OfficerZynerba Pharmaceuticals, Inc. (ZYNE) · full profile →Form 4 · filed Oct 11, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
3 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Oct 10, 2023Grant(A)85K——278K
Oct 10, 2023Tender(U)278K——0
Oct 10, 2023Tender(U)34K——193K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Oct 10, 2023Disposed to issuer(D)200K——0

Transaction Codes

A
Grant / award
U
See SEC Form 4 code table
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001140361-23-047729) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML